Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Proteragen
Beijing, Beijing, Chinaproteragen.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
Proteragen is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies targeting the complement system and other immune-mediated pathways. The company leverages a proprietary drug discovery platform to develop a robust pipeline of monoclonal antibodies and small molecules for rare diseases and ophthalmology. Its lead programs include inhibitors of Complement C5 and Factor B, aimed at treating conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Proteragen operates with a global footprint, maintaining research and development facilities in both China and the United States.
- Therapeutic areas
- HematologyNeurologyOphthalmology
- Modalities
- Monoclonal antibodyRecombinant proteinSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Proteragen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proteragen.